Zusammenfassung
Mehr als 85% aller bösartigen Nierentumoren sind Nierenzellkarzinome. Sarkome, Nephroblastome, Lymphome und Metastasen anderer Organtumoren sind selten, aber differenzialdiagnostisch zu berücksichtigen.
Der Beitrag widmet sich neben den Risikofaktoren für dieses urologische Malignom der Diagnostik und Therapie sowie der Prognose und den Erfordernissen der Nachsorge. Breiten Raum nehmen auch die Pathologie und Klassifikation ein. Spezielle Erwähnung finden das Rezidiv sowie das metastasierte Nierenzellkarzinom.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ (2005) Randomized Phase II/III Trial of Interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma. The European Organisation for research and treatment of cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23: 4171–4178
Abouassaly R, Yang S, Finelli A, Kulkarni GS, Alibhai SM (2011) What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU Int 108 (8 Pt 2): E223–31
Abukora F, Nambirajan T, Albqami N, Leeb K, Jeschke S, Gschwendtner M, Janetschek G (2005) Laparoscopic nephron sparing surgery: evolution in a decade. Eur Urol 47: 488–493
Ahrar K, Martin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME: Percutaneous radiofrequency ablation of renal tumors: technique, complications and outcome. J Vasc Interv Radiol 2005; 16: 679–688
Akubakr YA, Ia-Hsu C, Redman B (1994) Spontaneous remission of renal cell carcinoma: a casse report and immunological correlates. J Urol 152: 156–157
Alexander RB, Linehan WM (1993) Editorial comment. J Urol 150: 1390
Althausen P, Althausen A, Jennings LC, Mankin HJ (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80: 1103–9
Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D (2006) Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience. HPB (Oxford) 8 (2): 100–5
Alves A, Adam R, Majno P et al. (2003) Hepatic resection fo metastatic renal tumors: is it worthwhile? Ann Surg Oncol 10: 705–710
Amato RJ, Morgan M, Rawat A (2006) Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 106 (7): 1498–1506
Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177–186
Amato RJ (2003) Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 46: 59–65
Amato RJ, Harris P, Dalton M, et al. (2007) A phase II trial of intrapatient dose-escaleted sorafenib in patients (pts) with metastatic renal cell cancer /MRCG). Proc Am Soc Clin Oncol J Clin Oncol 25: 5026
Amedola MA, King IR, Pollack HM, Gefter W, Kressel HY, Wein AJ (1990) Staging of renal carcinoma using magnetic resonance imaging at 1.5 Tesla. Cancer 66: 40–44
Anast JW, Stoller ML, Meng MV, Master VA, Mitchell JA, Bassett WW, Kane CJ (2004) Differences in complications and outcomes for obese patients undergoing laparoscopic radical, partial or simple nephrectomy. J Urol 172 (6 Pt 1): 2287–91
Anderson CM, Pusztai L, Palmer JL, Cabanillas, F, Ellerhorst JA (1998) Coincident renal cell carcinoma and non Hodgkin’s lymphoma: the M.D. Anderson experience and review of the literature. J Urol 159: 714
Andrews DW, Scott CB, Sperduto PW et al. (2004) Whole brain radiation therapy with or without sterotactic readiosurgery boost for patients with one to three brain metastases. phase III results of the RTOG 9508 randomised trial. Lancet 363: 1665–1672
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (9422): 1665–72
Angervall I, Wahlquist I (1978) Follow-up and prognosis of renal carcinoma in a series operates by perifascial nephrectomy combined with adrenalectomy and retroperitoneal lymphadenectomy. Eur Urol 4: 13
Aoki S, Hattori R, Yamamoto T, Funahashi Y, Matsukawa Y, Gotoh M, Yamada Y, Honda N (2011) Contrast–enhanced ultrasound using a time–intensity curve for the diagnosis of renal cell carcinoma. BJU Int 108 (3): 349–54
Aso Y, Homma Y (1992) A survery on incidental renal cell carcinoma in Japan. J Urol 147: 340–343
Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M (2007) Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 84: 1114–1120
Assikis VJ, Daliani D, Pagliaro L et al. (2003) Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Prog Am Soc Clin Oncol 22: 286 (Abstr 1552)
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (10): 3714–21
Atkins MB (2009) Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 26 Suppl 1: 18–22
Atwell TD, Farrell MA, Callstrom MR, Charboneau JW, Leibovich BC, Patterson DE, Chow GK, Blute ML (2007) Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience. Radiology 243: 267–283
Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML, Charboneau JW (2008) Percutaneous renal cryoablation: experience treating 115 tumors. J Urol 179: 2136–2141
Atzpodien J, Buer J, Sel S, Jansen J, Oevermann K (1999) Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma. Urologe A 38 (5): 474–478
Atzpodien J, Hänninen EL, Kirchner H et al. (1995) Multiinstitutional home-therapy trial of recombinant interleukin-2 and I nterferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13 (2): 497–501
Atzpodien J, Kirchner H, Hänninen EL et al. (1999) European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 20 (Suppl 9): 22–26
Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2 and interferon alfa-2a-bases immunotherapy in advances renal cell carcinoma: a prospective randomized trial of the German Cooperative renal carcinoma chemoimmunotherapy group. J Clin Oncol 22 (7): 1188–1194
Atzpodien J, Körfer A, Franks CR, Pliwoda H, Kirchner H: Home therapy with recombinant interleukin-2 and interferon-alpha-2b in advanced human malignancies. Lancet 1990; 335: 1509–1512
Atzpodien J, Royston R, Wandert T, Reitz M and DGCIN – German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (2003) Metastatic renal carcinoma comprehensive prognostic system. B J of Cancer 88: 348–353
Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Wöltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M, DGCIN- German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (2005) Adjuvant treatment with interleukin-2 and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). B J of Cancer 92: 843–846
Au, KS, Hebert A, Roach ES, Northrup H (1999) Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet 65: 1790
Audenet F, Yates DR, Cancel–Tassin G, Cussenot O, Rouprêt M (2011) Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int doi: 10.1111/j.1464–410X.2011.10661.x. [Epub ahead of print]
Aulitzky W, Gastl G, Aulitzky WE et al.: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of IFN-γ. J Clin Oncol 1989; 7: 1875–1884
Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A (2007) Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 14: 1095–1097
Bajorin D, Sell KW, Richard JM et al. (1990) A kine-activated killer cells vs. interleukin-2 alone in renal cell carcinoma [abstract 1106]. Proc Am Assoc Cancer Res 31: A 1106
Bander NH (1987) Monoclonal antibodies: state of the art. J Urol 137: 603–612
Barama A, St-Louis G, Nicolet V, Hadjeres R, Daloze P (2005) Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant 5 (12): 3015–8
Becker F, Siemer S, Hack M, Humke U, Ziegler M, Stöckle M (2006) Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm. Eur Urol 49: 1058–1064
Bectol RE, Zagorie RJ (1997) Imaging approach to staging of renal cell carcinoma. Urol Clin North Am 24: 507–522
Bedke J, Pritsch M, Buse S, Jakobi H, Elsaesser KH, Pahernik S, Haferkamp A, Hofenfellner M (2008) Prognostic Stratification of localized renal cell carcinoma by tumor size. J Urol 180: 62–67
Beisland C, Medby PC, Beisland HO (2004) Presumed radically treated renal cell carcinoma-recurrence of the disease and prognostic factors for subsequent survival. Scand J Urol Nephrol 38 (4): 299–305
Beisland C, Talleraas O, Bakke A, Nordstein J (2006) Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 698–702
Belldegrun A, Koo AS, Bochner B, Figlin R, de Kernion JB (1990) Immunotherapy for advanced renal cell cancer the role of radical nephrectomy. Eur Urol 18 (2): 42–45
Belldegrun A, Pierce W, Kaboo R et al. (1993) Interferon-αlpha primed tumor infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell cardinoma. J Urol 150: 1384–1390
Belldegrun A, Webb DF, Austin III HA, Steinberg SM, Linehans WM, Rosenberg SA (1989) Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pretherapy nephrectomy. J Urol 141–499–503
Benichou J, Chow W-H, McLaughlin JK, Mandel JS, Fraumeni JF Jr. (1998) Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol 14: 424–430
Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A, Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M, Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ (2010) Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron–sparing surgery. Eur Urol 57 (3): 466–71
Benway BM, Bhayani SB, Rogers CG, Porter JR, Buffi NM, Figenshau RS, Mottrie A (2010) Robot–assisted partial nephrectomy: an international experience. Eur Urol 57 (5): 815–20
Berdjis N, Hackenberg OW, Zastrow S, Oehlschläger S, Novotny V, Wirth MP (2006) Impact of resection margin status after enphron sparing surgery for renal cell carcinoma. BJU International 97: 1208–1201
Berg-Schlosser V (1998) Radiologische Diagnostik maligner Nierentumoren. Dtsch Ärztebl 85: 390–394
Berntsen A, Geertsen PF, Svane IM (2006) Therapeutic dendritic cell vaccination of patients with renal cell carcinomas. Eur Urol 50: 34–43
Bex A, Blank C, Horenblast S, Haaren J (2006) Downsizing of unresectable primary metastatic renal cell cancer by sunitinib. A retrospective study. ASCO GU 8; 394
Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB (2010) Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol 49 (4): 520–3
Boorjian SA, Sengupta S, Blute ML (2007) Renal cell carcinoma: vena caval involvement. BJU Int 99: 1239–1244
Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP (1996) Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological and genetic features. Am J Pathol 149: 1201
Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schroder FH, de Prijck L (1999) Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36: 570–575
Blom JH, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L, Sylvester R; EORTC Genitourinary Tract Cancer Group (2009) Radical nephrectomy with and without lymph–node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55 (1): 28–34
Bloom DA, Kaufmann JJ, Smith RB (1981) Late recurrence of renal tubular carcinoma. J Urol 126: 546–648
Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU International 94: 33–41
Bodmer et al. (2002) Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11: 2489–2498
Brausi MA, Gavioli M, de Luca G, Verrini G, Peracchia GC, Simonini GL, Viola M (2007) Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrativi transitional cell carcinoma (TCG) of the upper urinary tract: Impact of Survival. Eur Urol 52: 1414–1420
Brenner H, Stegmaier C, Ziegler H (2005) Long-term survival of cancer patients in Germany achieved by the beginning of the third millennium. Ann Oncol 16 (6): 981–6
Bretan PN, Busch MP, Hricak H (1986) Development of a acquired renal cysts an renal cell carcinoma. Cancer 57: 1871–1879
Brinkmann OA, Bruns F, Gosheger G, Micke O, Hertle L (2005) Treatment of bone metasases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation. World J Urol 23 (3): 185–90
Brkovic D, Riedasch G, Waldherr R, Röhl I, Staehler G (1994) Lokale Rezidive nach orgenerhaltender Nierentumorchirurgie. Urologe A 33: 104–109
Brunelli M, Eble JM, Zhang S, Martignoni G, Delahunt B, Cheng L (2004) Eosinophilic and classis chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10 and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol 18: 161–169
Bruno JJ, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastases on survival. BJU International 97: 933–938
Bruntsch U, Heinrich B, Kaye SB et al. (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A: 1067–1067
Bülow H, Sebeikat D, Demetriou D (1991) Ist die Adrenalektomie bei der Tumornephrektomie immer erforderlich? Urologe A 30: 341–343
Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol. 2011 Dec; 60 (6): 1163–70
Buse S, Bedke J, Kurosch M, Haferkamp A, Unterberg A, Herfarth K, Hohenfellner M (2007) Hirnmetastasen beim Nierenzellkarzinom. Urologe A 46: 36–39
Campbell SC, Novick AC, Herts B, Fischler DF, Meyer J, Levin HS et al. (1997) Prospective evaluation of fine needle aspiration on small, solid renal masses: accuracy and morbidity. Urology 50: 25
Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG (2006) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1–2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175 (3 Pt2): 864–9
Carini M, Seli C, Barbanti G, Iapini A, Turini D, Costatini A (1988) Sonservative surgical treatment of renal cell carcinoma: clinical experience and reappraisal of indications. J Urol 140: 725–731
Carl P, Klein U, Gebauer A, Schmiedt E (1977) The value of lymphography for the TNM classification of renal carcinoma. Eur Urol 3: 286–288
Castilla EA, Liou LS, Abrahams NA (2002) Prognostic importance of resection margin after nephron-sparing surgery for reanl cell carcinoma. Urology 60: 993–997
Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26 (22): 3763–9
Cestari A, Guazzoni G, Dell’Acqua V, Nava L, Gardone G, Balconi G, Naspro R, Montorsi F, Rigatti P (2004) Laparoskopic cryoablation of solid renal masses: intermediate term followup. J Urol 173: 1267–1270
Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21 (5): 884–890
Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG (2011) Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60 (5): 964–71
Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta analysis and review of the world literature. J Urol 175: 425–431
Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B (1995) Germline mutations in the Von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Human Mutation 5: 66–75
Chen WS, Farrow GM, Zincke H (1991) The incidence of multientricity in renal cell carcinoma. J Urol 146: 1221–1223
Choueiri TK, Garcia JA, Elson P, et al. (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543–550
Choueiri TK, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, Hussein MA (2008) An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 101 (6) 712–715
Choueiri TK, Plantade A, Elson P, Negrier S et al. (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26: 127–131
Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185 (1): 60–6
Chow WH, Devesa SS, Warren JL, Fraumeni JF (1999) Rising Incidence of renal cell cancer in the United States. Jama 281: 1628–31
Chu TM, Rupnick MA, Kerkela R et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011–2019
Choyke PL, Glenn G, Walther MM et al. (2003) Hereditary renal cancers. Radiology 22: 33–46
Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guillé F, Abbou CC, Salzano L, Gallo C (2005) Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104: 1362–71
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CPG, McDermott D, Smith JW, Gordon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trail. J Clin Oncol 21 (6): 3133–3140
Cohen AJ, Frederick P, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS (1979a) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 13: 592–5
Cohen AJ, Li FP, Berg S et al. (1979b) Hereditary renal cell carcinoma ssociated with a chromosome translocation. N Engl J Med 301: 592
Cohen D, Zhou M (2005) Molecular genetics of familial renal cell carcinoma syndromes. Clin Lab Med 25 (2): 259–77
Cooper CS, Cohen MB, Donovan JF (1996) Splenectomy complicating left nephrectomy. J Urol 155: 30–36
Coppin C, Porzsolt F, Awa A, Kumpf J, Goldman A, Wilt T (2004) Immunotherapy for advances renal cell cancer. Cochrane Database System Rev 3: CD001425
Corman JM, Penson DF, Hur K, Khuri SF, Daley J, Henderson W, Krieger JN (2001) Comparison of complications after radical and partial nephrectomy: results from the National Veterns Administration Surgical Quality Improvement Program. BJU Int 88 (1): 126
Cost NG, Delacroix SE Jr, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V (2011 = The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59 (6): 912–8
Crispen PL, Uzzo RG (2007) The natural history of untreated renal masses. BJU Int 99: 1203–1207
Czenne K, Hemminki K (2003) Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden. J Urol 169: 1271–1275
Dall’Oglio MF, Antunes AA, Sarkis AS, Crippa A, Leite KR, Lucon AM, Srougi M (2007) Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 100: 552–555
Dalla-Palma L, Pozzi-Mucelli F, di Donna A, Pozzi-Mucelli RS (1990) Cystic renal tumors: US and CT findings. Urol Radiol 12: 67–73
Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (12): 3623–33
Dash A, Vickers AJ, Schachter LR Bach AM, Snyder ME, Russo P (2006) Comparison oft outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm. BJU International 97: 939–945
De Baere T, Risse O, Kuoch V et al. (2003) Adverse events during radiofrequency treatment of 582 hepativ tumors. AJR Am J Roentgenol 181: 695–700
De Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP (1988) Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 4 (3): 149–154
De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J (1996) Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491–495
Dechet CB, Zincke H, Sebo TJ, King BF, LeRay AJ, Farrow GM et al. (2003) Prospective analysis of computerized tomography and needles biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 169: 71
DeKernion JB, Berry D (1980) The diagnosis and treatment of renal cell carcinoma. Cancer 45: 1947–56
DeKernion JB, Huland H (1990) The operable renal cell carcinoma: Summary and conclusions. Eur Urol 2: 48–51
DeKernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma. a computer analysis. J Urol 120: 148–152
Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney Am et al. (2005) Prospective randomized comparison of transperitoneal vs. retrioperitoneal laparoscopic radical nephrectomy. J Urol 173: 38–41
Dexeus FH, Logothetics CJ, Sella A et al. (1991) Circadian infusion of floxuridin in patients with metastatic renal cell carcinoma. J Urol 146: 709–713
Dillenburg W., Dillenburg W, Poulakis V, Skriapas K, de Vries R, Ferakis N, Witzsch U, Melekos M, Becht E (2006) Retroperitoneoscopic vs. open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: quality of life, pain and reconvalescence. Eur Urol 49: 314–323
Diller R, Gruber A, Wolters H, Senninger N, Spiegel HU (2005) Therapy and prognosis of tumors of the genitorurinary tract after kidney transplantation. Transplant Proc 37 (5): 2089–92
Dineen MK, Pastore RD, Emrich IJ, Huben RP (1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. Urol 140: 277–279
Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S (2009) Phase II study of sorafenib in patients with sunitinib–refractory metastatic renal cell cancer. J Clin Oncol 27 (27): 4469–74
Di Silverio F, Sciarra A, Parente U, Andrea A, von Heland M, Panebianco V, Passariello R (2008) Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 80: 451–453
Drachenberg D, Childs RW (2003) Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma. Cancer Treat Res 116: 213–226
Dranoff G et al. (1983) Vaccination with irradiated tumor engineered to secrete murine granulozyte-macorphage colony-stimulating factor simulated potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90 (8): 339
Dunn J (2000) Laparoscopic vs. open radical nephrectomy: a 9-year experience. Urol 164: 1153–1159
Durr HR, Maier M, Pfahler M, Baur A, Refior HJ (1999) Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop 367: 283–290
Dutcher JP, Szczylik C, Tannir N et al. (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advandes renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Proc Am Soc Clin Oncol J Clin Oncol 25: 5033
Ebert T, Schnell D, Weissbach L (2005) Lymph node dissection in patients with renal cell carcinoma Urologe A 44 (6): 635–7
Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101–3106
Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100 (20): 1454–63
Elson PJ, Witte RS, Trump DI (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310–7313
Eschenbach AC von, Avallone A, Price J, Swanson D, Killion J, Stephenson R, Fidler IJ (1990) The biology of renal cancer the influence of nephrectomy. Eur Urol 18 (2): 40–41
Escudier B, Choueiri TK, Oudard S, Szczylik C, Negrier S, Ravaud A, Chevreau C, Vener P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM (2007) Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 178: 1901–1905
Escudier B, Pluzanska A, Koralewski P et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27 (20): 3312–8
Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa–2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 1; 28 (13): 2144–50
Faivre S, Kroemer G, Raymond E (2006) Current developments of mTOR inhibitors as anticancer agents. Nat Rev Drug Discovery 5: 671–688
Fakhrai N, Haitel A, Balassy C, Zielinski CC, Schmidinger M (2005) Major response and clinical benefit following third-line treatment for Bellini duct carcinoma. Wien Klin Wochenschr 117: 63–65
Falchrai H, Shawlet DI, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE (1995) Cytokine gene therapy with interleukin-2 transduced fibroblasts: Effect of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591–601
Fein AB, Lee JKT, Balte DM et al. (1987) Diagnosis and staging of renal cell carcinoma: a comparison of MR imaging and CT. Am J Roentgenol 148 (4): 749–753
Fergany AF, Hafez KS, Novick AC (2000) Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 163 (2): 442–5
Fergany AF, Saad IR, Woo L, Novick AC (2006) Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases. J Urol 175: 1630–1633
Ficarra V, Martignoni, G, Lohse C, Novara G, Pea M, Cavalleri S, Artibani W (2006) External validation of the Mayo Clinic Stage. Size, Grade and Necrosis (SSIGN) score to predict cancer-specific survival using a European series of conventional renal cell carcinoma. J Urol 175: 1235–1239
Ficarra V, Galfano A, Mancini M et al. (2006) Reassesing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49: 324–331
Ficarra V, Novara G (2008) The new medical treatment of metastatic renal cell carcinoma: A good debut, a lot of open questions. Eur Urol 54: 252–255
Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, Artibani W (2009) Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron–sparing surgery. Eur Urol 56 (5): 786–93
Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8 (+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158: 740–745
Filipas D, Spix C, Schulz-Lampel D, Michaelis J, Hohenfellner R, Roth S, Thuroff JW (2003) Screening for renal cell carcinoma using ultrasonography: a feasibility study. BJU Int 91: 595–9
Finley DS, Beck S, Box G, Chu W, Deane L, Vajgrt DJ, McDougall EM, Clayman RV (2008) Percutaneous and laparoscopic cryoablation of small renal masses. J Urol 180: 492–498
Firek P, Richter S, Jaekel J, Brehmer B, Heidenreich A (2012) Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors. Urologe A 51 (3): 398–402.
Fischer CG, Wächter W, Fuenctecilla PE, Miller J, Weidner W, Dudeck J (1997) Urologische Tumore in Deutschland. Urologe A 36: 143–150
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–9
Flanigan RC, Yonover PM (2001) The role of resection for patients with renal carcinoma. Curr Oncol Rep 3: 424–32
Fleischmann JD, Kim B (1991) Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145: 938–41
Flocks RH, Kadesky MC (1958) Malignant neoplasmas of the kidney: an analysis of 353 patients followed 5 years or more. J Urol 79: 196
Fossa SD (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27 (2): 187–193
Forges et al. (1988) Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 4: 149–154
Fourquier P, Regnard JF, Rea S, Levi JF, Levasseur P (1997) Lung metastases of renal cell carcinoma: results of surgical resection. Eur J Cardiothorac Surg 11: 17–21
Fowler JE Jr (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135: 22–25
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2003) Solid renal tumors: an analysis of pathological features relates to tumor size. J Urol 170: 2217–2220
Frank I, Colombo JR, Rubinstein M, Desai M, Kaouk J, Indesbir S (2006) Laparoscopic partial nephrectomy for centrally located renal tumors: Frank I, Colombo JR, Rubinstein M, Desai M, Kaouk J, IS Gill. J Urol 175: 849–852
Freed SZ, Halperin JP, Gordon M (1977) Idiopathic regression of metastases from renal cell carcinoma. J Urol 118: 538–42
Fuzesi L, Gunawan B, Braun S et al. (1994) Renal oncocytoma with a translocation t (9; 11) (p23; q13). J Urol 152: 471–472
Fyfe GA, Fisher RI, Rosenberg SA et al. (1996) Long-term response data for 255 atients with metastatic renal cell carcinoma treated with high-does recombinant interleukin-2 therapy. J Clin Oncol 14: 2410–2411
Galfano A, Novara G, Iafrage M, Cavalleri S, Martignoni G, Gardiman M, D’Elia C, Patard JJ, Artibani, W, Ficarra V (2008) Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 80: 113–123
Gansbacher B (1992) A Pilot study of immunization with IL-2 secreting allogeneic HIA-A2 matched renal cell carcinoma cells in patients with advances renal cell carcinoma. Hum Gene Ther 3 (6): 691–703
Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI (2010) Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116 (23): 5383–90
Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B et al. (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52 (22): 6229–6236
George CM, Volgelzang NJ, Rini BI, Geofffroy FJ, Kollipara P, Stadler WM (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13: 116–120
George S, Pili R, Carducci MA, Kim JJ (2011) Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 9 (9): 1011–8
Gerst S, Hann LE, Li D, Gonen M, Tickoo S, Sohn MJ, Russo P (2011) Evaluation of renal masses with contrast–enhanced ultrasound: initial experience. AJR Am J Roentgenol 197 (4): 897–906
Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR (2005a) Radiofrequency ablation of renal cell carcinoma: part 2, lessons learned with ablation of 100 tumors. AJR 185: 72–80
Gervais DA, Arellano RS, Mueller PR (2005b) Percutaneous radiofrequency ablation of renal cell carcinoma. Eur Radol 15: 960–967
Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: Part I, Indications, Results, and Role in Patient Managemtn over a 6-Year Period and Ablation of 100 Tumors. AJR 185: 64–71
Ghavamian R, Cheville JC, Lohse CM, Weaver AL, Zincke H, Blute ML (2002) Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol 168 (2): 454–9
Gill IS, Martin SF, Desai MM, Kaouk JH, Steinberg A, Mascha E, Thornton J, Sherief MH, Strzempkowski B, Novick AC (2003) Comparative analysis of laparoscopic vs. open partial nephrectomy for renal tumors in 200 patients. J Urol 170 (1): 64–8
Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV (1994) Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography: J Urol 152: 1082–1085
Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick AC (2005) Renal cryoablation: outcome at 3 years. J Urol 173: 1903–1907
Gill, IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo Jr. JR, Frank I, Permpongkosol S, Weight CJ, Kaouk JH, Kattan W, Novick AC (2007) Comparison of 1,800 laparoscopic and open partial nephrectomy for single renal tumors. J Urol 178: 41–46
Gill IS, Kamoi K, Aron M, Desai MM (2010) 800 Laparoscopic partial nephrectomies: a single surgeon series. J Urol 183 (1): 34–41
Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, Lorenzo-Romero JG, Donate-Moreno MJ, Pastor-Navarro H, Garcia-Olmo DC, Escribano-Martinez J, Virseda-Rodriguez JA (2006) Determination of vhl Gene Mutations in Sporadic Renal Cell Carcinoma. Eur Urol 49: 1051–1057
Giuliani I, Giberti C, Martorane G, Rovida S (1990) Radical estensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143: 468–474
Glassberg KI (2002) Renal dysplasis and cystic disease of the kidney. In: Campbell’s Urology, 8. edn. Elsevier Science, pp 1443–1495
Gleave ME, Elhilali M, Fradet Y et al. and the Canadian Urologic Oncology Group (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338: 1265–1271
Glenn GM, Linehan WM, Hosoe S et al. (1992) Screening for von Hippel-Lindau disease by DNA-polymorphism analysis. JAMA 267: 1226–31
Gnarra J, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florecne C, Pozzatti R, Walther MM, Bander NH, Grossmann HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lermann MI, Zbar B, Linehan WM (1994) Mutations of the VHL tumor suppressor gene in renal carcinoma. Natur Genetics 7: 85–90
Gnarra JR, Tory K, Weng Y et al. (1994) Mutations fo the von Hippel-Lindau tumor suppressor gene in renal carcinoma. Nat Genet 7: 85
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risk of death, cardiovascular events, and hospitilization; N Engl J Med 351: 1296–305
Goering JD, Mahvi DM, Niederhuber JE, Chicks D, Rikkers LF (2002) Cryoablation and liver resection for noncolorectal liver metastases. Am J Surg 183: 384–389
Gogus C, Baltaci S, Beduk Y, Sahinli S, Kupeli S, Gogus O (2003) Isolated local recurrence of renal cell carcinoma after radical nephrectomy: experience with 10 cases. Urology 61: 926–9
Goldfarb DA, Novk AC, Lorig R et al. (1990) Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venocavography and computerized tomography scanning. J Urol 144: 110–1104
Golimbu M, AlAskari S, Tessler A, Morale P (1994) Aggressive treatment of metastatic renal cancer. J Urol 136: 805–807
Golumbek PI et al. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254 (5032): 713–716
Gofrit ON, Shapiro A, Pizov G, Landau EH, Katz R, Zorn KC, Pode D (2007) Does stage T3a renal cell carcinoma embrace a homogeneous group of patients? J urol 177: 1682–1686
Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.J Clin Oncol 27: 235–41
Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF (2010) Interferon alfa–2a vs. combination therapy with interferon alfa–2a, interleukin–2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open–label randomised trial. Lancet. 375 (9715): 641–8
Gorge DG, Michaelson MD, Rosenberg JE, et al. (2007) Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoms (mRCC). Proc Am Soc Clin Oncol J Clin Oncol 25: 5035
Greene FL, Gospodarowicz MK, Wittekend C (2009) American Joint Committee on Cancer (AJCC) Staging Manual, 7th edn. Springer, Philadelphia
Grigon DJ, Ayala AG, ElNaggar A et al. (1989) Renal cell carcinoma – a clinico pathologic and DNA flow cytometric analysis of 103 cases. Cancer 64: 2133–2140
Grossmann HB, Sommerfeld D, Konnak JW, Bromberg J (1994) Long-term assessment of renal function following nephrectomy for state I renal carcinoma. Br Urol 74: 279–282
Gupta A, Allaf ME, Kavoussi LR, Jarrett TW, Chan DYS, Su LM, Solomon SB (2006) Cumputerized tomography gruides percutaneous renal cryoablation with the patient under conscious sedation: initial clinical experience. J Urol 175: 447–453
Hafez KS, Fergary AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162 (6): 1930–1933
Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28 (13): 2131–6
Hansel DE (2006) Genetic alterations and histopathologic findings in familial renal cell carcinoma. Histol Histopathol 21 (4): 437–44
Hatcher PA, Anderson EE, Pauson DF et al. (1991) Surgical management and prognosis of renal cell carcinoma invading the vana cava. J Urol 145: 20–24
Heidenreich A, Ravery V; European Society of Oncological Urology (2004) Preoperative imaging in renal cell cancer. World J Urol. 22 (5): 307–15
Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H; Association of Urologic Oncology of the German Cancer Society (2010) Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 85 (1): 1–10
Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T (2011) Renal cell carcinoma in octogenarians: nephron sparing surgery should remain the standard of care. J Urol 185: 415–420
Hellsten S, Johnsen J, Berge T, Linell F (1990) Clinically unrecognized renal cell carcinoma. Eur Urol 18 (2): 2–3
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Clin Oncol 27 (34): 5794-
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM, Baylin SB (1994) Silencing of the VHL tumor-suprressor gene by DNA methylation in renal carcinoma. Genetics 91: 9700–04
Hermanek P, Schrott KM (1990) Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 144: 238–242
Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metatatic renal cell carcinomas. J Clin Oncol 21 (20): 3770–3776
Herring JC, Enqust EG, Chernoff A et al. (2001) Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 165: 777–781
Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extendes dissection of the regional lymph nodes in the therapy of renal cell carcinoma? J Urol 146: 1224–1227
Hino O, Kobayashi T, Okimoto K (2006) Genetic and environmental factors in hereditary predisposition to tumors: a conceptual overview. EXS 96: 269–92
Hitt E (2003) Low-dose thalidomide adds minimal benefit to patients with renal cell carcinoma taking interferon. J Clin Oncol 21 (20): 370–3776
Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the Unites States: an analysis of surveillance, epidemiology and end results program data. J Urol 167: 57–60
Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48 (1): 77–81
Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG (1996) Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 156 (1): 18–21
Höltl L, Zelle-Rieser C, Gander H, Papesh Ch, Ramoner R, Bartsch G, Rogatsch H, Barsoum AD, Coggin JH, Turnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dentritic cells. Clin Cancer Res 8: 3369–3376
Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human interferons in therapy of of urological cancers. J Urol 142: 173–1179
Hovsepian DM, Leva H, Amis ES Jr, Newhouse JH (1990) MR evaluation of renal space-occupving lesions: diagnostic criteria. Urol Radiol 12: 74–79
Hrushesky WJ, Von Roemeling R, Fraley EE, Rabatin JT (1988) Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol 4: 110–115
Huang WC, Levey AS, Serio AM, et al. (2006) Chronic kidney disease after nehrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7: 735–740
Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005) Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 114: 101–118
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O’Toole T, Kong S, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk pathets with advanced renal cell carcinoma (advRCC). J Clin Oncol 24 (Abstr. LBA4)
Huland E, Heinzer H, Mir TS, Huland H (1997) Inhales interleukin-2 in pulm, onary metastic renal-cell carcinoma: 6 years of expeience. Cancer J Sci Am 3: 98–105
Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal-cell carcinoma. J Urol 147: 344–348
Hulten I, Rosencrantz M, Seeman I, Wahlquist I, Ahren C (1969) Occurrence and localization of lymph node metastases in renal cell carcinoma. A lymphographic and histopathological investigation in connection with nephrectomy. Scand I Urol Nephrol 3: 129
Iliopoulos O, Kibel A, Gray S, Laelin WG Jr. (1995) Tumor suppression by the human von Hippel-Lindau gene product. Natur Medicine 1 (8): 822–6
Imamoglu MA, Bakirta H, Sagnak L, Tuygun C, Ersoy H (2002) A comparison of two different incisional approaches in the surgical treatment of renal cell carcinoma. Int Urol Nephrol 33 (1): 7–11
Ishikawa I, Ishii H, Shinoda A, Tateishi K, Ben A, Suzuki K, Tsugawa R (1991) Renal cell carcinoma of the native Kidney after renal transplantation. a case report and review of the literature. Nephron 58: 354–358
Ishikawa I, Saito Yasuhito, Shikura N, Kitada H, Shinoda A, Suzuki S (1990) Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 5: 452–458
Ito A, Satoh M, Ohyama C, Saito S, Shintaku I, Nakano O, Aoki H, Hoshi S, Orikasa S (2002) Adrenal metastasis from renal cell carcinoma: significance of adrenalectomy. Int J Urol 9: 125–8
Itano NB, Blute ML, Spotts B, Zincke H (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–5
Jakse G (1989) Operative Technik beim Nierentumor mit Cavathrombus. Aktuel Urol 20: V–X
Janetschke G, Jeschke K, Peschel R, Strohmeyer D, Henning K, Bartsch G (2000) Laparoscopic surgery for T1 renal cell carcinoma. Eur Urol 38: 131–138
Jarret TW, Sweetser PM, Weiss GH, Smith AD (1995) Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol 154: 1629–1635
Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51: 203–205
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249
Jeong IG, Jeong CW, Hong SK, Kwak C, Lee E, Lee SE. (2006) Prognostic implication of capsular invasion without perinephric fat infiltration in localized renal cell carcinoma.Urology. 67: 709–712
Jermann M, Stahel RA, Salzberg M et al. (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advance, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57 (4): 533–539
Jeschke K, Peschel R, Wakonig J, Schellander L, Bartsch G, Henning K (2001) Laparoscopic nephron-sparing surgery for renal tumors. Urology 58: 688–692
Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, Tanguay S, Rendon RA, Gleave ME, Drachenberg DE, Chow R, Chung H, Chin JL, Fleshner NE, Evans AJ, Gallie BL, Haider MA, Kachura JR, Kurban G, Fernandes K, Finelli A (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 60 (1): 39–44
Jimenez RE, Eble JN, Reuter VE, Epstein JI, Folpe AL, de Peralta-Venturina M, Tamboli P, Ansell ID, Grignon DJ, Young RH, Amin MB (2001) Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol14: 157–63
Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrewski G, Schmitt E, Danneberg T, Lehmacher W, von Wietersheim J Doehn C (2004) Adjuvant autologous renal cell vaccine in patients with renal cell carcinaoma after radical nephrectomy : phase III, randomised controlled trial. Lancet 363: 594–599
Johnson CD, Donnick NR, Cohan RH et al. (1987) Renal adenocarcinoma: CT staging of 100 tumors. Am J Roentgenol 148 (1): 59–63
Kang DE, White RL, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma. J Urol 171: 1806–1809
Kantor AF (1977) Currant concepts in the epidemiology and etiology of primary renal cell carcinoma. J Urol 117: 415–417
Kaouk JH, Hillyer SP, Autorino R, Haber GP, Gao T, Altunrende F, Khanna R, Spana G, White MA, Laydner H, Isac W, Stein RJ (2011) 252 robotic partial nephrectomies: evolving renorrhaphy technique and surgical outcomes at a single institution. Urology 78 (6): 1338–44
Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P (2008) Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53: 845–848
Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, de la Tialle A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25: 1316–1322
Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Schips L, Zigeuner R, Mulders PFA, Valeri A, Descotes JL, Mejean A, Patard JJ (2007) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 51: 1616–1624
Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y (2004) Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol 172 (3): 863–6
Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (1): 63–67
Kavoussi IR, Kerbl K, Capelouto CC, McDougall EM, Glayman RV (1993) Laparoscopic nephrectomy for renal neoplasms. Urology 42: 603–609
Kawai K, Saijo K, Oikawa T, Ohno T, Akaza H (2004) Enhancement of T cell proliferative response against autologous cancer cells of a metastatic renal cell carcinoma patient after unexplained regression. Int J Urol 12: 1130–1132
Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T (2011) Sequential FDG–PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17 (18): 6021–8
Kerbl K, Clayman RV, McDougall et al. (1994) Transperitoneal nephrectomy for benign disease of the kidney: a comparison of laparoscopic and open surgical techniques. Urology 43: 607–613
Kessler OJ, Mukamel E, Weinstein R, Gayer E, Konichezky M, Servadio C (1998) Metachronous renal cell carcinoma metastasis to the contralateral adrenal gland. Urology 51: 539–43
Kierney PC, van Heerden JA, Segura JW, Weaver AL (1994) Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1: 345–52
Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS (2004a) Prognostic signifi-cance of venous thrombus in renal cell carcinoma. Are renal vein and inferior cave involvement different ? J Urol 171: 588–591
Kim JK, Park SY, Shon JH, Cho KS (2004b) Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. Radiology 230: 677–84
Kim HL, Seligson D, Liu X Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173: 1496–1501
Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, de la Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ (2007) Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 177: 2081–2087
Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS (2007) Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 178 (4 Pt 1): 1189–95
Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrierei G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2008) Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol 179: 1719–172
Klatte T, Grubmüller B, Waldert M, Weibl P, Remzi M (2011) Laparoscopic cryoablation vs. partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. Eur Urol 60 (3): 435–43
Kletscher BA, Quian J, Bostwick DG, Blute MI, Zincke H (1996) Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol 155: 1844
Kochhar R, Brown RK, Wong CO, Dunnick NR, Frey KA, Manoharan P (2010) Role of FDG PET/CT in imaging of renal lesions. J Med Imaging Radiat Oncol 54 (4): 347–57
Kopka L, Fischer U, Zoeller G, Schmidt C, Ringert RH, Grabbe E (1997) Dual-phase helical CT of the kidney: value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR Am J Roentgenol. 169: 1573–8
Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS (2007) Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol 177 (2): 466–70
Kovacs G, Brusa P, de Riese W (1989) Tissue-specific expression of a constitutional 3; 6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 43: 422–427
Kovacs G, Fuzesi L, Emanuel A, Kung F (1991) Cytogenetics of papillary renal cell tumors. Genes, chromosome & cancer 3: 249–255
Kuczyk M, Wegener G., Jonas U (2005) The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 48 (2): 252–7
Kuczyk MA, Köhn G, Höfner K, Machtens S, Bokermeyer C, Stief CG, Truss MC, Schäfers HJ, Hartmann JT, Jonas U (1998) Prognostische Relevanz des Kavathrombus beim Nierenzellkarzinom. Urologe A 37: 299–305
Kuhn FP, Altwein JE (1980) Nierenadenome: Dignität, Klinik und Therapie: Urol Int 35: 258–270
Kühn R, Bornhof Ch, Giedl J (1991) Klinik und Wertigkeit renaler Onkozytome. Urologe A 30: 357–340
Kumar S, Duque JL, Guimaraes KC, Dicanzio J, Loughlin KR, Richie JP (1999) Short and long-term morbidity of thoracoabdominal incision for nephrectomy: a comparison with the flank approach. J Urol 162 (6): 1927–9
Kunkle DA, Crispen PL, Li T, Uzzo RG (2007) Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 177: 1692–1697
Kunkle DA, Greenberg RE, Chen DYT, Uzzo RG (2007) Clinical characteristics of enhancing renal masses which do not demonstrate interval growth. J Urol 177: 849–85
Kural AR, Atug F, Tufek I, Akpinar H (2009) Robot–assisted partial nephrectomy vs. laparoscopic partial nephrectomy: comparison of outcomes. J Endourol 23 (9): 1491–7
Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182 (3): 844–53
Lager DJ, Slagel DD, Palechek PL (1994) The experience of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod athol 7: 544–548
Lam CW, To KF, Tong SF (2006) Genome-wide detection of allelic imbalance in renal cell carcinoma using high-density single-nucleotide polymorphism microarrays. Clin Biochem 39 (3): 187–90
Lam JS, Klatte T, Patard JJ, Goel RH, Guille F, Lobel B, Abbou CC, de la Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Paryer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin RA, Belldegrun AS (2007) Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 52: 155–162
Lam JS, Klatte T, Kim HL, et al. (2008) Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Ondol/Hematol 65: 235–262
Lane BR, Samplaski MK, Herts BR et al. (2008) Renal mass biopsy – a renaissance? J Urol 179: 20–27
Lane BR, Chen H, Morrow M, Anema JG, Kahnoski RJ (2011) Increasing use of kidney sparing approaches for localized renal tumors in a community based health system: impact on renal functional outcomes. J Urol 186 (4): 1229–35
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W. Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, McClellan MW, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov Ilya, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–20
Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H (2000) Matched comparison of radical nephrectomy vs nephron-sparing surgery in patinets with unilateral renal cell carcinoma and noraml contralateral kidney. Mayo Clin Proc. 75: 1236–1242
Lau WK, Zincke H, Lohse CM, Cheville JC, Weaver AL, Blute ML (2003) Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int 91: 775–9
Laudano MA, Klafter FE, Katz M, McCann TR, Desai M, Benson MC, McKiernan JM (2008) Pathological tumour diameter predicts risk of conventional subtype in small renal cortical tumours. BJU Int 102 (10): 1385–8
Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E et al. (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98: 3387
Law CH, Wei AC, Hanna SS et al. (2003) Pancreatic resection for metastatic renal cell carcinoma. Presentation, treatment, and outcome. Ann Surg Oncol 10: 922–926
Lawatsch EJ, Langenstroer P, Byrd GF, See WA, Quiroz FA, Begun FP (2006) Intermediate results of laparoscopic cryoablation in 59 patients at the Medical college of Wisconsin. J Urol 175: 1225–1229
Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2006) Positron emission tomography (PET), immuno-PET and radioimmunotherapy in reanal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU International 97: 916–922
Lebret T, Poulain JE, Moilinie V et al. (2007) Percutaneous core biopsy for renal masses. Indication, accuracy and results : J Urol 178: 1184–1188,
Lee SE, Kim HH (1994) Validity of kidney-preserving surgery for localized renal cell carcinoma. Eur Urol 25: 204–208
Leibovich B, Blute MI, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97: 1663–1671
Leibovich BC, B lute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2004) Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm. Results in outcome similar to radical nephrectomy. J Urol 171: 1066–70
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML (2005) A scoring algorithm to predict survival for patients with metatatic clear cell carcinoma: a stratification tool for prospective clinical trials. JUrol 174: 1759–1763
Lendvay TS, Marshall FF (2003) The tuberous sclerosis complex and ist highly variable manifestations. J Urol 169: 1635–1642
Lerner et al. (1996) Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 155: 1868–1873
Levens W, Rübben H, Ingenhag W (1989) Long-term interferon treatment in metastativ renal cell carcinoma. Eur Urol 16: 378–381
Levi F, Lucchini F, Negri E, La Vecchia C (2004) Declinino mortalità from kidney cancer in Europe. Ann Oncol 15 (7): 1130–5
Levine E, Slusher SL, Grantham JJ et al. (1991) Natural history of acquired renal cystic disease in dialysis patients. Am J Roentgenol 156: 501–506
Levine E (1992) Renal cell carcinoma in uremic acquired renal cystic disease: incidence, detection and management. Urologic Radiol 13: 203–210
Levinson AK, Johnson DE, Strong IC, Pathak S, Huff V, Saunders GF (1990) Familial renal cell carcinoma: hereditary or coincidental? J Urol 144: 849–851
Levinson AD, Su LM, Agarwal D, Sroka M, Jarrett TW, Kavoussi LR, Solomon SB (2008) Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 180: 499–504
Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180: 510–514
Li FP, Decker HJH, Zbar B, Stanton VP, Kovacs G, Seizinger BR, Aburatani H, Sandberg AA, Berg S, Hosoe S, Brown RS (1993) Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3; 8 translocation. Annals of Internal Medicien 118: 106–11
Licht MR, Novick AC, Goormastic M (1994) Nephron sparing surgery in incidental vs. suspected renal cell carcinoma. J Urol 152: 39–42
Lien YHH, Kam I, Shanley PF, Schröter GPJ (1991) Metastatic renal cell carcinoma associated with acquired cystic kidney disease 15 years after successful renal transplantation. Am J Kidney Dis 6: 711–715
Lindblad P (2004) Epidemiology of renal cell carcinoma. Scand J Surg 93 (2): 88–96
Linehan WM, Grubb RL, Coleman JA, Zbar B, McClellan MW (2005) The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int J 95 (Suppl 2): 2–7
Ljungberg B, Stenlig R, Roos C (1986) Prognostik value of deoxyribonucleic acid analysis in state I renal cell carinoma. J Urol 136: 801–814
Ljungberg B, Holmberg G, Sjödin JG, Hietala SO, Stenling R (1990) Renal cell carcinoma in a renal cyst: a case report and review of the literature. J Urol 143: 797–799
Ljungberg B, Larsson P, Stenling R, Roos G (1991) Flow cytometric desyribonucleic acid analysis in stage I renal cell carcinoma. J Urol 146: 697–699
Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58 (3): 398–406
Lonser R, Glenn G, Walther MM et al. (2003) Von Hippel-Lindau disease. Lancet 361: 2059–67
Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) WHO classification of the renal tumors of the adults. European Urology 49: 798–805
Lucas SM, Stern JM, Adibi M, Zelster IS, Cadeddu JA, Raj GV (2008) Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and exstirpative techniques. J Urol 179: 75–80
Maher ER, Iselius L, Yates JRW, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28: 443–7
Mahnken HA, Tacke J (2006) Renal tumors. Recent results Cancer Res 167: 123–133
Mahnken AH, Rhode D, Brkovic D, Günther RW, Tacke JA (2005) Percutaneous radiofrequency ablation of renal cell carcinoma: preliminary results. Acta Radiol 46: 208–214
Malek RS, Omess PJ, Benson RC Jr, Zinke H (1987) Renal cell carcinoma in von Hippel-Lindau-Syndrome. Am J Med 82: 236–240
Maloney KE, Norman RW, Lee CLY, Millard OH, Welch JP (1991) Cytogenetic abnormalities associated with renal cell carcinoma. J Urol 146: 692–696
Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Négrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng DY, Choueiri TK, Motzer R, Bukowski R; International Kidney Cancer Working Group (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17 (16): 5443–50
Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN (2012) Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti–angiogenic treatment. BJU Int 109 (2): 200–6
Maranchie JK, Alfonso A, Albert P et al. (2004) Solid renal tumor severity in von Hippel-Lindau disease is related to germline delection length and location. Human Mutation 23: 40–6
Marberger M (1988) Organerhaltende Nierentumorexzision. Akt Urol 19 (2): 58–66
Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150: 463–6
Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Woods CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell Carcinoma. J Urol 180: 94–98
Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181: 2044–51
Marshall FF, Ferguson J, Reitz BA (1990) Operative management of renal cell carcinoma with suprahepativ intracaval neoplastic extension. Eur Urol 18 (2): 26–28
Marshall FF, Powell KC (1982) Lymphadenectomy for renal cell carcinoma: anatomical and therapeutic considerations. J Urol 128: 677–681
Marshall FF (1993) Editorial comment. J Urol 150: 323
Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinger AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG (2003) Allogenetic dendritic cells fudes with tumor cells: preclinical results and outcome of a clinical phase I/II triall in patients with metastatic renal cell carcinoma. Hum Gene Ther 14 (5): 483–494
Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, Jewett MA, Klotz L, Rendon RA (2011) Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 59 (5): 863–7
Matson MA, Cohen EP (1990) Acquired cystic kidney disease: occurence, prevalence and renal cancers. Medicine 69 (4): 217–226
Mattar K, Bosiuk J, Finelli A, et al. (2008) Active surveillance of small renal masses : a prospective multic-centre Canadian traial. Eur J Urol 7 (Suppl3): 309
Maturen KE, Nghiem HV, Caoili EM et al. (2007) Renal mass core biopsy: accuracy and impact on clinical management. Am J Roentgenol 188: 563–570
Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ (2003) Image-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. Am J Roentgenol 180: 1503–1508
McCabe M, Stablein D, Hawkins MJ (1991) The modified Group C experience – phase III randomized trials of IL-2 vs. IL-2/LAK in advanced renal cell cancer and advanced melanoma [abstract 714]. Proceedings of the American Society of Clinical Oncology 10: 213
McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy or advances renal cell carcinoma: evidence for the polyclonality of metastases. Cancer 47: 1984–1987
McDermott DF, Regan MM, Clark J et al. (2005) Randomized phase III trial of high-dose interleukin-2 vs. subcutaneous IL-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (1): 133–141
McDonald JC, McDonald AD, Hughes JM, Rando RJ, Weill H (2005) Mortality from lung and kidney disease in a cohort of North American industrial sand workers: an update. Ann Occup Hyg 49 (5): 367–73
McGahan JP, Lamba R, Fisher J, Starshak P, Ramsamooj R, Fitzgerald E, Yen P (2011) Is segmental enhancement inversion on enhanced biphasic MDCT a reliable sign for the noninvasive diagnosis of renal oncocytomas? AJR Am J Roentgenol 197 (4): W674–9
McLaughlin JK, Blot WJ, Devesa SS, Fraumeni JF Jr. (1996) Renal cancer. In: Schottenfeld D, Fraumeni JF Jr. (eds) Cancer Epidemiology and Prevention, 2nd edn. New York, NY: Oxford University Press, pp 1142–1155
McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P (2002) Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 60: 1003–9
McNichols DW, Segura JW, DeWeerd JH (1981) Renal cell carcinoma: long-term survival and late recurrence. J Urol 126: 17–23
Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23: 832–841
Mellemgaard A, Moller H, Olsen J, Jenson O (1991) Increased risk of renal cell carcinoma in obese women. J Natl Cancer Inst 83: 1581
Messing EM, Manola J, Wilding G, et al. (2003) Phase III study of interferon alfa-NL as adjuvant for respectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–70
Middleton RG, Presto AJ (1973) Radical thoracoabdominal nephrectomy for renal cell cancer. J Urol 110: 36
Middleton RG (1967) Surgery for metastatic renal cell carcinoma. J Urol 97: 973–977
Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM (2002) Active chemotherapy for collecting duct carcinoma of the kidney: a case report und reviwe of the literature. Cancer 94: 111–116
Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, Sirzén F (2011) Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 29 (1): 83–8
Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS; Urologic Diseases in America Project (2008) Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 112: 511–520
Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, Miura T, Makiyama K, Yao M, Kubota Y, Inoue T (2010) Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast–enhanced CT. Clin Nucl Med 35 (12): 918–23
Mittelmann A, Hubermann M, Puccio C et al. (1990) A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 66: 664–669
Miyao N, Masiumori N, Takahasi H et al. (1998) Lymph node metastasis in patients with carcinoma of the renal pelvis and ureter. Eur Urol 33: 180–185
Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Wisss experience with 588 tumors. Cancer 89: 604–614
Moinzadeh A, Gill IS, Finelli A, Kaouk J, Desai M (2006) Laproscopic partial nephrectomy: 3-year follow-up. J Urol 175: 459–462
Moinzadeh A, Libertino JA (2004) Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same. J Urol 171: 598–601
Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ (2012) Phase II trial of sunitinib in patients with metastatic non–clear cell renal cell carcinoma. Invest New Drugs 30 (1): 335–40
Moll V, Becht E, Zieler M (1993) Kidney preserving surgery in renal cell tumors: indications, technique and results in 152 patients. J Urol 150: 319–323
Möller JD, Esteve J, Möller H, Renrd H (1990) Cancer in the European Community and ist member states. Eur J Cancer 6 (11/12): 1167–1256
Montie JE, Novick AC (1988) Partial nephrectomy for renal cell carcinoma. J Urol 140: 129–130
Montie JE, Stewart BH, Straffon RA, Banowsky LHW, Hewitt CB, Montague DK (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma J Urol 117: 272–275
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognosis stratification of 670 patients with advances renal cell carcinoma. J Clin Oncol 17 (8): 2530–2540
Motzer RJ, Bacik J, Murphy BA, Russo P, Pazumdar M (2002) Interferon-αlfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289–296
Motzer RJ, Bacik J, Mariani T et al. (2002) Treatment outcome and survival with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20 (9): 2376–2381
Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma. N Engl J Med 335: 865–875
Motzer RJ, Mihcaelson MD, Redman BG et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell cardinoma. J Clin Oncol 24 (1): 16–24
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski OR, Qudard S, Kim ST, Baum CM, Figlin RA (2007) Sunitinib vs. interferon alfa in metastatic renal cell carcinoma. N Eng J Med 356: 115–124
Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA (2009) Phase I trial of sunitinib malate plus interferon–alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 7 (1): 28–33
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (22): 3584–90
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD-.1 Study Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116 (18): 4256–65
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First–Line Therapy for Advanced Renal Cell Carcinoma. J Clin Oncol 30 (12): 1371–7
Mues AC, Landman J (2010) Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines. Curr Opin Urol 20: 105–110.
Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ (1994) A phase II trial of vinblastine plus dipyrimadole in advanced renal celllcarcinoma. Am J Clin Oncol 17: 10–13
Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM et al. (2005) Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 79 (3): 996–1003
Muss HB (1987) Interferon therapy for renal cell carcinoma. Semin Oncol 14 (2): 34–42
Nadler RB, Loeb S, Clements JQ, Batler RA, Gonzalez CM, Vardi IY (2006) A prospective study of laparoscopic radical nephrectomy for T1-tumors – Is transperitoneal, retroperitoneal or hand assited the best approach? J Urol 175: 1230–1234
Naito S, Kimiya K, Sakamoto N et al. (1991) Prognostic factors and value of adjunctive nephrectomy in patients with state IV renal cell carcinoma. Urology 37: 95–99
Nambirajan T, Jeschke S, Al-Zahrani H, Vrabes G, Leeb K, Janetschek G (2004) Prospective randomized controlled study : transperitoneal laparoscopic vs. retroperitoneoscopic radical nephrectomy. Urology 64: 919–924
Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101 (7): 1545–51
Navai N, Wood CG (2012) Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol 30 (2): 220–4
Negrier S, Caty A, Lesimple T, Doullard JY, Escudier B, Rossi JF, Viens P, Gomez F for the Groupe Francais d’Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18: 4009–4015
Negrier S, Escudier B, Lasset C et al. (1998) Recombinat human interleukin-2, recombinant human interferon alfa-2a, or both in metastativ renal-cell carcinoma. N Engl J Med 338: 1272–1278
Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12 (7): 673–80
Neri B, Doni L, Gemelli MT, Fulignati C, Turrini M, Di Cello V, Dominici A, Maleci M, Mottola A, Ponichietti R, Raugei A, Valsuani G, Cini G (2002) Phase II trial of weekly intravenoud gemcitabine administratiojn with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. J Urol 168: 956–958
Neuhaus C, Dijkhuizen T, van den Berg E et al. (1997) Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review. Cancer Genet Cytogenes 94: 95–98
Neumann HPH, Wiestler OD (1991) Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337: 1052–54
Neves RJ, Zincke H, Taylor WF (1988) Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 139: 1173–1176
Nguyen CT, Lane BR, Kaou, JH, Hegarty N, Gill IS, Novick AC, Camphell SC (2008) Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol 180: 104–109
Nickerson ML, Warren MB, Toro JR et al. (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2: 157–64
Novick AC, Streem S, Montic JE, Pontes JE, Siegel S, Montague DK, Goormastic M (1989) Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 141: 835–839
Novick AC (1991) Possibilities and limitations of partial nephrectomy for renal cell carcinoma. Curr Opin Urol 1: 30–3
Nurmi MJ, Puntala PV, Tyrkko JE, Antila LE (1985) Transabdominal and lumbar nephrectomy for renal adenocarcinoma. Scand J Urol Nephrol 19 (2): 129–31
O’Dea et al. (1978) The treatment of renal cell carcinoma with solitary metastasis. J Urol 120: 540–542
O’Malley RL, Godoy G, Kanofsky JA, Taneja SS (2009) The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 181: 2009–1
O’Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W 3rd, Pili R, Schwaab T (2011) Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78 (3): 595–600
Ogan K, Cadeddu JA, Stifelman MD (2003) Laparoscopic radical nephrectomy: oncologic efficacy Urol Clin N Am 30: 543–550
Ogawa O, Habuchi T, Kaheki Y, Koshiba M, Sugiyana, Yoshida O (1952) Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p1. Cancer Resaerch 52: 1881–85
Ohlmann CH, Ozgür E, Schrader AJ, Konrad L, Hofmann R, Engelmann U, Heidenreich A (2006) Detection of circulating tumor cells in patients with renal cell carcinoma by reverse transcriptase polymerase chain reaction for G250/MNCA–9: results of a prospective trial. Urol Oncol 24 (4): 287–93
Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA (2012) Radiofrequency ablation vs. partial nephrectomy in patients with solitary clinical t1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol 61 (6): 1156–61
Ono Y, Kinukawa T, Hattori R (1999) Laparoscopic radical nephrectomy for renal cell carcinoma : a five year experience. Urology 53: 280–286
Oosterwijk-Wakka C, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruynce FM, de Mulder PH, Oosterwijk E, Mulders PE (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase I study. J Immunother 25: 500–508
Paganini-Hill A, Ross RK, Henderson BE (1988) Epidemiology of renal cancer. In: Skinner DG, Lieskovksy G (eds) Treatment of genitourinary cancer, Saunders, Philadelphia
Pahernik S, Roos F, Wiesner C, Thüroff JW et al. (2007a) Nephron sparing surgery for renal cell carcinoma in solitary kidney. Wold J Urol 25: 513–517
Pahernik S, Cudovic D, Roos F et al. (2007b) Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU Int 100: 26–29
Pantuck AJ, Zisman A, Belldegrun AS (2001) Biology of renal cell carcinoma: chaning concepts in classification and staging. Semin Urol Oncol 19 (2): 72–79
Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA (2003) Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97: 2995–3002
Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169: 2076–83
Pareek G, Hedican SP Jason RG, Bruskewitz RC, Nakada SY (2006) Meta-Aanlysis of the complications of laparoscopic renal surgery: Comparison of procedures and techniques. J Urol 175: 1208–1213
Parek DJ, Lin WC, Herrell SD (2005) Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality. J Urol 174: 1754–1758
Park BK, Kim SH, Choi HJ (2005) Characterization of renal cell carcinoma using agent detection imaging: comparison with gray-scale US. Korean J Radiol 6: 173–8
Parker JE, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP (2004) History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 59: 42–48
Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, de la Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulder PF, Belldegrun AS (2004) Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171: 2181–2185
Patard JJ (2006) Prognostic and biological significance of lymph node spreading in renal cell carcinoma. Eur Urol 49: 220–222
Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J (2011) ICUD–EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol 60 (4): 684–90
Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA Jr, Barocas DA (2012) National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol 187 (3): 816–21
Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7 (1): 24–7
Paul R, Mordhorst J, Busch R et al. (2001) Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm. J Urol 166: 59–62
Pavlovich CP, Grubb RL 3rd, Hurley K, Glenn GM, Toro J, Schmidt LS, Torres-Cabala C, Merino MJ, Zbar B, Choyke P, Walther MM, Linehan WM (2005) Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173 (5): 1482–6. Erratum in: J Urol 174 (2): 796
Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of nrel-cell carcinoma. Nat Rev Cancer 4: 381–393
Pavlovich CP, Walther MM, Eyler RA et al. (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26: 1542–1552
Perez-Farinos N, Lopez-Abente G, Pastor-Barriuso R (2006) Time trend and age-period-cohort effect on kidney cancer mortality in Europe, 1981–2000. BMC Public Health 6 (1): 199
Peyromaure M, Thiounn N, Scotte F, Vieillefond A, Debre B, Oudard S (2003) Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 170: 1138–1140
Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74: 1653–1657
Pfannschmidt J, Klode J, Muley T, Dienemann H, Hoffmann H (2006) Nodal involvement at the time of pulmonary metastasectomy: experiences in 245 patients. Ann Thorac Surg 81 (2): 448–54
Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumor volume removed. BJU Int 100: 755–759
Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schiildberg FW, Fuerst H (2003) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Sorg 73: 1082–1087
Piper NY, Bishoff JT, Magee C (2001) Is a 1 cm margin necesssary during nephron-sparing surgery for renal cell carcinoma ? Urology 58: 849–852
Piper C, Pfister D, Porres D, Mahnken A, Brehmer B, Heidenreich A (2012) Organ-preserving renal tumor surgery for renal cell carcinoma â¥T1b : Operative technique, complications and oncological control. Urologe A 51 (4): 539–43
Pizzocaro G, Piva I, Salvoni R, di Fronzo G, Ronchi E, Miodini P and the Lombardy Group (1986) Adjuvant medroxyprogesterone acetate and steroid hormone receptors in category Mo renal cell carcinoma. An interim report of a prospective, randomized study. J Urol 135: 18–21
Pizzocaro G, PÖiva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubine E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 (2): 425–431
Pomer S, Schirrmacher V, Thiele R, Löhrke H, Brkovic D, Staehler G (1995) Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous τ-II-2 and IFN-alpha 2b. Int J Oncol 6: 947–954
Ponti G, Ponz de LM, Losi L, Di Gregorio C, Benatti P, Pedroni M, Scarselli A, Riegler G, Lembo L, Pellacani G, Seidenari S, Rossi G, Roncucci L (2006) Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. Br J Dermatol 152 (6): 1335–8
Poppel H van, Bamelis B, Baert L (1997) Elective nephron-sparing surgery for renal cell carcinoma. Eur Urol 6: 8–12
Poston CD, Jaffe GS, Lubensky IA et al. (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153: 22–6
Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treatd with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53: 376–381
Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O’Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A (2011) The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 60 (3): 448–54
Prestl JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldmann F (2002) Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 167: 1464–1468
Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN (2009) Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 29 (6): 1565–74.
Provet J, Tessler A, Brown J, Golimbu M, Bosniak M, Morales P (1991) Partial nephrectomy for renal cell carcinoma: indication, results and implications. J Urol 145: 472–476
Pyrhonen S, Salminen E, Lethonen T, Nurmi M, Tammela T et al. (1996) Recxombinant interferon-alpha 2a with vinblastine vs. vinblastine alone in advances renal cell carcinoma. A phase III study. Am, Soc Clin Oncol 15: abstr 614
Pyrhonen S, Salminen E, Rutuu M, Lethonen T, Nurmi M, Tammely T (1999) Prospective randomized trial of interferon-alpha 2a plus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–2867
Rabbani F, Grimaldi G, Russo P (1998) Multiple primary malignancies in renal cell carcinoma. J Urol 160:
Rabbani F, Herr HW., Almahmeed T, Russo P (2002) Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographie factors. J. Clinical Oncol 20 (9): 2370–5
Rabbani F, Reuter VE, Katz J, Russo P (2000) Second primary malignancies associated with renal cell carcinoma: influence of histological type. Urology 56: 399
Rafla S (1970) Renal cell carcinoma: natural history and results of treatment. Cancer 25: 26
Rainwater IM, Hosaka Y, Farrow GM, Lieber MM (1987) Well differentiated clear cell renal carcinoma: significance of nuclear deoxyribonucleic acid patterns studied by flow cytometry. J Urol 137: 15–20
Rassweiler J, Henkel IO, Potempa DM, Copcoat MJ, Miller D, Preminger GM, Alken P (1993) Transperitoneal laparoscopic nephrectomy: training, technique, ans results. J Endoruol 7: 505–515
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JI, Xia C, Simantov R, Schwartz B, O’Dwyer J (2006) Phase II Placebo-Controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (16): 1–7
Rathmell K, Amin C, Wallen E, Pruthi R (2008) Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). ASCO A370
Ravaud A, Delva R, Gomez F et al. (2002) Sucutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma – less efficacy compared to intravenous interlukin-2 and interferon α. Results of a multicenter Phase II trial form the Groupe Francais d’Immunothérapie. Cancer 95 (11): 2324–2330
Ravaud A, Dilhuydy MS (2005) Interferon alpha for treatment of advances renal cancer. Expert Opin Biol Ther 5 (6): 749–762
Reichelt O, Gajdba M, Chyhrai A, Wunderlich H, Junker K, Schubert J (2007) Ultrasound-guides biopsy of homogenous solid renal masses. Eur Urol 52: 1421–1427
Reiter Re, Zbar B, Linehan WM (1993) Molecular genetic studies of renal carcinoma: potential biologic and clinical significance for genitourinary malignancy. In: Walsh PC, Retik AB, Vaughan ED, Stamey TA (eds) Cembell’s Urology; 3th ed. Sauders, Philadelphia, pp 1–15
Rendon RA, Jewett MAS (2006) Expectant management for the treatment of small renal masses. Urol Oncol 24: 62–67
Repassy DL, Becsi A, Tamas G, Weninger T (1999) Comparison of morbidity of lumbar flank approach and transperitoneal approach for radical nephrectomy. Acta Chir Hung 38 (3–4): 311–20
Raymond VM, Herron CM, Giordano TJ, Gruber SB (2012) Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. Fam Cancer 11 (1): 115–21
Riccabona M, Szolar D, Preidler K, Uggowitzer M, Kugler C, Dorfler O, Schreyer HH (1999) Renal masses–evaluation by amplitude coded colour Doppler sonography and multiphasic contrast-enhanced CT. Acta Radiol 40: 457–61
Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18: 2419–2426
Rini BI, Zimmermann T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinicl results. J Clin Oncol 20: 2017–24
Rini BI, Wilding GT, Hudes G, Stadler WM, Kim S, Tarazim JC, Bycott PW, Liau KF, Dutcher JP (2007) Axitinib (AG-013736: AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25 (185): 5032
Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177: 1978–1984
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa vs. interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1; 28 (13): 2137–43
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 (9807): 1931–9
Ritchie AWS, Cisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10: 390–400
Ritchie AWS, Griffiths G, Cook P, Oliver RTD et al. (1998) Alpha interferon improves survival in patients with metastatic renal carcinoma – preliminary results of an MRC randomised controlled trial. Am Soc Clin Oncol abstr. 1194
Rixe O, Bukowski RM, Mihchaelson MD, Wilding G, Huded GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axinitib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8: 975–984
Robey EL, Schellhammer PE (1986) The adrenal gland and renal cell carcinoma: is ipsi lateral adrenalectomy a necessary component of radical nephrectomy? J Urol 135: 453–457
Robson CJ, Churchill BM, Anderson W (1969) The restuls of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301
Rohde D, De Mulder PH, Weissbach L, Osieka R, Blatter J, Jakse G (1996) Experimental and clinical efficacy of 2’,2’-difluorodeoxycytidine (gemcitabine) against renal cell carcinoma. Oncology 53: 476–481
Rohde D, Thiemann D, Wildberger J, Wolff J, Jakse G (1998) Treatment of renal cell cancer patients with gemcitabine and interferons: antitumor activity and toxicity. Oncol Re5: 1555–1560
Roos FC, Pahernik S, Elsäßer A, Victor A, Brenner W, Thüroff JW (2008) Imperative organerhaltende Nierentumorchirurgie bei Einzelniere bzw. bilateralen Tumoren. Langzeitergebnisse. Der Urologe 7: 818–823
Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin alone. N Engl J Med 316: 889–897
Rosenberg SA, Lotze MT, Yang JD et al. (1993) Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancers. J Nathl Cancer Inst 85: 622
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321
Rosenberg MD, Kim CY, Tsivian M, Suberlak MN, Sopko DR, Polascik TJ, Nelson RC (2011) Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol 196 (4): 935–9
Rosenthal EI, Kraft R, Zingg EJ (1984) Organ-preserving surgery in renal cell carcinoma: tumor enucleation vs. partial kidney resection. Eur Urol 10: 222–228
Rosser CJ, McCullough DL, Hall MC (2000) Thoracoabdominal radical nephrectomy: is a postoperative thoracotomy tube necessary? Urology 55 (6): 847–51
Roth JS, Rabinowitz AD, Benson M et al. (1993) Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 20: 1055–58
Ruiz JL, Vera C, Server G, Osca JM, Boronat F, Jimenez Cruz JF (1991) Renal cell carcinoma: late recurrence in 2 cases. Eur Urol 20: 167–169
Russo P (2008) Should elective partial nephrectomy be performed for renal cell carcinoma >4 cm in size? Nat Clin Pract Urol 5: 482–483
Sablin MP, Bouaita L, Balleyguier G et al. (2007) Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients: Proc Am Soc Clin Oncol J Clin Oncol 25: 5038
Sagalowsky AK, Kadesky KT, Ewatt DM et al. (1994) Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 151: 1181–1184
Samplaski MK, Zhou M, Lane BR, Herts B, Campbell SC (2011) Renal mass sampling: an enlightened perspective. Int J Urol 18: 5–19
Sanchez de la Muela P, Zudaire JJ, Robles JE et al. (1991) Renal cell carcinoma: vena cava invasion and prognostic factors. Eur Urol 19: 284–290
Sanchez Y, El-Naggar A, Pathak S, McNeill Killary A (1994) A tumor suppressor locus with 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Genetics 91: 3383–87
Sanchez Y, El-Naggar A, Pathak, S, Killary AM (1994) A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci USA 91: 3383
Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prgnostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100: 556–560
Sardock DS, Settel AP, Resnick MI (1995) A new protocol for follow-up of renal cell carcinoma based pathological stage. J Urol 154: 28
Sarna G, Figlin R, de Kernion J (1987) Interferon in renal cell carcinoma. The UCLA experience. Cancer 59 (3 Suppl): 610–612
Satoh S, Tsuchiya N, Habuchi T, Ishiyama T, Seimo K, Katho T (2005) Renal cell and transitional cell carcinoma in Japanese population undergoing maintenance dialysis. J Urol 174: 1749–1753
Savage PD, Muss HB (1995) Renal cell cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biological Therapy of Cancer.Lippincott, Philadelphia, pp 373–387
Schauer M, Vogelsang H, Siewert JR (2008) Pancreatic resection for metastatic renal cell carcinoma: a single center experience and review of the literature. Anticancer Res 28: 361–365
Schendel DJ, Gansbacher B 1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interfern treatment. Cancer Res 53 (17): 4020–4025
Schlichter A, Wunderlich H, Junker K, Kosmehl H, Schubert J (1999) Limits for organ-preserving surgery in renal cell carcinoma. Urologe A. 1999 38: 479–85
Schlichter A, Wunderlich H, Junker K, Kosmehl H, Schubert J (2000) Where are the limits of elective nephron-sparing surgery in renal cell carcinoma? Eur Urol 37: 517–520
Schmidt L, Duh FM, Kishida T et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68–73
Schmidt LS, Warren MB, Nickerson ML et al. (2001) Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to thromosome 17p11.2. Am J Hum Genet 69: 876–882
Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R (2008) Metastatic non-clear cell renal cell carcinoma: current therapeutic option: BJU Int 101 (11): 1343–1345
Schraml P, Hergovich A, Hatz F, Amin MB, Lim SD, Krek W, Mihatsch MJ, Moch H (2003) Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. Am J Pathol 163: 1013–1020
Schrodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP (2007) Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 167: 1630–3
Sella A, Swanson DA, Ro JY, Putnam JB Jr, Amato RJ, Markowitz AB, Logothetis CJ (1993) Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 49: 19–21
Semelka RC, Shoenut JP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM (1993) Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 3: 597–602
Shalev M, Cipolla B, Buille F, Staerman E, Lobel B (1995) Is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol 153: 1415
Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98: 342–9
Sherry RM, Pass HI, Rosenberg SA, Yang JC (1992) Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69: 1850–1855
Sheth S, Scatarige JC, Horton KM et al. (2001) Current concepts in the diagnosis and management of renal cell carcinoma. role of multidetector CT and three-dimensional CT. Radiographics 21: 237
Shimizu M, Yokota J, Mori N et al. (1990) Introduction of normal chromosome 3p modulates the tumorgenicity of a human renal cell carcinoma cell line YCR. Oncogene 5: 185–194
Shingleton WB, Sewell PE (2001) Percutaneous cryoablation of renal tumors with magnetic resonance imaging guidance. J Urol 167: 1268–1270
Shuin T, Kondo K, Torigoe S et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852–5
Shvarts O, Tsui KH, Smith RB, Kernion JB, Belldegrun A (2000) Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. J Urol 164 (4): 1160–3
Siemer S, Lehmann J, Kamradt J et al. (2004) Adrenal metastases in 1635 patients with renal cell carcinoma. outcome and indication for adrenalectomy. J Urol 171: 2155–2159
Siminovitch JP, Montie JE, Straffon RA (1982) Lymphadenectomy in renal adenocarcinoma. J Urol 127: 1090
Simons J (1995) Phase I study of nun-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6: 347–368
Skinner DG, Colvin RB, Vermillon CD, Pfister RC, Leadbetter WI (1971) Diagnosis and management of renal cell carcinoma. Cancer 8: 1165–1177
Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, MCKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 (1): 48–51
Sowery RD, Siemens DR (2004) Growth characteristics of renal cortical tumors in patients manged by watchful waiting. Can J Urol 11: 2407–2410
Spiegel DM, Yuen-Ko JL, Hou SH, Brandt TD, Grant TH (1991) Incidence of renal cell carcinoma and natural history of acquired renal cystic desease in end-stage renal disease. Am J Nephrol 11: 166–167
Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman T, Vogelzang NJ (2003) Prognostic factors for survival with gemcitabine plus 5-fluorocil based regimens for metatstatic renal cancer. J Urol 170: 1141–1145
Staehler G, Drehmer I, Pomer S (1994) Tumorbefall der Vena cava beim Nierenzellkarzinom. Urologe A 33: 116–121
Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, et al. (2010) Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol 28 (4): 543–7
Steiner T, Knels R, Schubert J (2004) Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 46: 327–330
Stephenson AJ, Hakimi AA, Snyder ME, Russo P. (2004) Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol 171 (1): 130–4
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol 28 (6): 1061–8
Stief CG, Jahne J, Hagemann JH, Kuczyk M, Jonas U (1997) Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol 158: 375–7
Stifelman MD, Handler T, Nieder AM, Del Pizzo J, Taneja S, Sosa RE, Shichman SJ (2003) Hand-assisted laparoscopy for large renal specimens: a multi-institutional study. Urology.61: 78–82
Stillwell, TJ, Gomez MR, Kelalis PP (1987) Renal lesions in tuberous sclerosis. J Urol 138: 447
Stolle CA, Glenn G, Zbar B et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gne. Human Mutation 12: 417–23
Störkel S, Ebie JN, Adlakha K et al. (1997) Classification of renal cell carcinoma: workgroup no. 1, Union Internationale Contre le Cancer (UICG) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987–989
Störkel S, Thoenes W, Jacobi GH, Engelmann U, Lippold R (1990) Prognostic parameters of renal cell carcinoma. Eur Urol 18 (2): 36–37
Strohmeyer TG, Slamon DJ (1994) Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol 151: 1479–1497
Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, Zingg EJ (1990) Enlargement of regional nodes in renal cell carcinoma i soften not due to metastases. J Urol 144: 243–245
Su LM, Jarrett TW, Chan DY, Kavoussi LR, Solomon SB (2003) Percutaneous computed tomography –guided radiofrequency ablation of renal masses in high surgical risk patients. Preliminary results. Urology 61: 26–33
Sükösd F, Digon B, Fischer J, Pietsch T, Kovacs G (2001) Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet Cytogenet 128: 161–163
Sutherland SE, Resnik MI, MacLennan GT, Goldman HB (2002) Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter. J Urol 167: 61–64
Swanson DA, Borges PM (1983) Complications of transabdominal radical nephrectomy for renal cell carcinoma. J Urol 129: 704–707
Swanson DA (2004) Surgery for metastases of renal cell carcinoma. Scand J Surg 93 (2): 150–5
Szczylik G, Demkow T, Stähler M et al. (2007) Randomized phase II traial of first-line treatment with sorafenib vs. interferon in patients with advandes renal cell cardinoma. final results. Proc Am Soc Clin Onocl J Clin Oncol 25: 5025
Takatera H, Maeda O, Toshirsugu O et al. (1986) Solitary later recurrence of renal cell carcinoma. J Urol 136: 799–801
Talberg T, Tykkä H, Mahlberg K, Haltunnen P, Lehtonen I, Kalima I, Sama S (1985) Active specific immunotherapy with supportive measures in the treatment of palliatevely nephrectomized renal adenocarcinoma patients. A thirteen-year follow-up study. Eur Urol 11: 233–243
Tamai H, Takiguchi Y, Oka M, Shingaki N, Enomoto S, Shiraki T, Furuta M, Inoue I, Iguchi M, Yanaoka K, Arii K, Shimizu Y, Nakata H, Shinka T, Sanke T, Ichinose M (2005) Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. J Ultrasound Med. 24: 1635–40
Tammela ILJ, Leinomen ASS, Konturi MJ (1991) Comparison excretory urography, angiography, ultrasound and computed tomography for I category staging of renal cell carcinoma. Scand J Urol Neprhol 25: 283–286
Tamaskar H, Garcia JA, Elson P Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM (2008) Antitumor effects of sunitinib of sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81–86
Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96: 579–92
Terrone C, Guercio S, De Luca S, et al. (2003) The nunmber of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 91: 37–40
Terrone C, Gontero P, Volpe A, Porpiglia F, Bollito E, Zattoni F, Frea B, Tizzani A, Fontana D, Scarpa RM, Rossetti SR (2008) Proposal of an improved prognostic classification for pT3 renal cell carcinoma: J Urol 180: 72–78
Taneja SS, Pierce WW, Figlin R, Belldegrun A (1994) Management of disseminated kidney disease. Urol Clin North Am 21: 625–637
Tanguay S, Swanson DA, Putnam JB (1996) Renal cell carcinoma metastatic to the lung: potential benefit in the combination to biological therapy and surgery. J Urol 156: 1586–1589
Tate R, Iddenden R, Harnden P, Morris E, Craigs C, Bennett C, Brook C, Haward RA, Forman D (2003) Increased incidence of renal parenchymal carcinoma in the Northern and Yorkshire region of England, 1978–1997. Eur J Cancer 39 (7): 961–7
Terrone C, Cracco C, Guercio S, Bollito E, Poggio M, Scoffone C, Tarabuzzi R, Porpiglia F, Scarpa RM, Fontana D, Rocca Rossetti S (2004) Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 46: 472–6
Thelen A, Jonas S, Benckert C, Lopez-Hanninen E, Rudolph B, Neumann U et al. (2007) Liver resection for metastases from renal cell carcinoma. World J Surg 31 (4): 802–7
Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA; Multiple Leiomyoma Consortium (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Gent 30: 1–5
Thoenes W, Störkel S, Rumpelt HJ (1986) Histopathology of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125–143
Thomas AA, Aron M, Hernandez AV, Lane BR, Gill IS (2009) Laparoscopic partial nephrectomy in octogenarians. Urology 74: 1042–1046
Thompson IM, Peek M (1988) Improvement in survival of patients with renal cell carcinoma – the role of the serendipitously detected tumor. J Urol 140: 187–190
Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I (2007) Dynamic outcome prediction in patients with clear cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 177: 477–480
Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, Nogueira L, Reuter VE, Russo P (2009) Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 181 (5): 2033–6
Thrasher JB, Robertson JE, Paulson DF (1994) Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 43: 160–168
Tolia BM, Whitmore WF Jr. (1975) Solitary metastasis from renal cell carcinoma. J Urol 114: 836–8
Toro JR, Nickerson ML, Wie MH et al. (2003) Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in north america. Am J Hum Genet 73: 95–106
Tosaka A, Ohya K, Yamada K, Ohashi H, Kitahara S, Sekine H, Takehara Y, Oka K (1990) Incidence and properties of renal massas and asymptomatic renal cell carcinoma detected by abdominal ultrasonogrpahy. J Urol 144: 1097–1099
Tourani JM, Pfister C, Berdah JF et al. (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 16: 2505–2513
Tsui KH, Shvarts O, Barbaric Z et al. (2000) Is adrenalectomy a necessary component auf radical nephrectomy; UCLA experience with 511 radical nephrectomies. J Urol 163: 437–441
Tunuguntla HSGR, Jorda M (2008) Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 179: 2096–2102
Turna B, Frota R, Kamoi K, Lin YC, Aron M, Desai MM, Kaouk JH, Gill IS (2008) Risk factor analysis of postoperative complications in laparoscopic partial nephrectomy. J Urol 179: 1289–1295
Tykkä H, Oravisto KJ, Lehtonen T, Sarna S, Tallberg T (1978) Active specific immunotherapy of advanced renal cell carcinoma. Euro Urol 4: 250–258
Ueda T, Yasumasu T, Uozomi J, Naito S (1991) Comparison of clinical and pathological characteristics in incidentally detected and suspected renal carcinoma. Br J Urol 68: 470–472
Unnithan JS, Choueiri T, Garcia J, Dreicer R, Laura W, Bukowski R, Rini B (2007) Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic remal cell carcinoma (mRCC) and central nervous system (CNS) metastases. J Clin Urol ASCO 25: 18S: 5047
Uzzo RG, Cherullo EE, Myles J, Novick AC (2002) Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol. 167: 2392–6
Uzzo RG (2005) Renal cell carcinoma: urologists in a new era. J Urol 174: 1723–1724
Valle L, Cascon A, Melchor L, Otero I, Rodriguez-Perales S, Sanchez L, Cruz Cigudosa J, Robledo M, Weber B, Urioste M, Benitez J (2005) About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t (3; 8) (p14.1; q24.23) family. Eur J Hum Genet 13 (5): 570–8
van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, Weterman M, Ligtenberg M, Smeets D, Smits A (1999) Renal cell cancer: chromosome 3 translocations as risk factors. J Nat Cancer Inst 91: 1159–1160
Van Poppel H, Claes H, Willemen P, Oyen R, Baert I (1991) Is there a place for conservative surgery of renal carcinoma? Br Urol 67: 129–133
van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessen I, Sylvester R (2007) A prospective randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. Eur Urol 51: 1606–1615
Veltri A, Garetto I, Tosetti I, Busso M, Volpe A, Pacchioni D, Bollito E, Papotti M (2011) Diagnostic accuracy and clinical impact of imaging–guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 21 (2): 393–401
Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentelly detected small renal masses. Cancer 100: 738–745
Volpe A, Kachura JR, Geddie WR, et al. (2007) Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 178: 379–386
Vasudevan A, Davies RJ, Shannon BA, Cohen RJ (2006) Incidental renal tumors: the frquency of benign lesions and the role of preoperative core biopsy. BJU International 97: 946–949
Viterbo R, Chawla S, Crispen P et al. (2005) Delayed management of incidentally detected renal masses does not limit or cimplicate treatment options. J urol 173: 23 A 82
Volkmer BG, Gschwend JE (2002) Value of metastases surgery in metastic renal cell carcinoma. Urologe A 41: 225–230
Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MAS (2004) The natural history of incidentally detected small renal masses. Cancer 100 (4): 738–745
von Knobloch R, Schrader AJ, Walthers EM, Hofmann R (2009) Simultaneous adrenalectomy during radical nephrectomy for renal cell carcinoma will not cure patients with adrenal metastasis. Urology 73: 333–6
Waers JS, Moss C, Hackett S et al. (2003) A phase II trial of gemcitabine (GEM) plus cepecitabine (CAPE) in patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 22: 386 (Abstr 1549)
Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM (1995) Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinomaand no renal disease: Clinical implications. J Urol 154: 2010–5
Washecka R, Hanna M (1991) Malignant renal tumors in tuberous sclerosis. Urology 4: 340–343
Washio M, Mori M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, Miki T, Nakao M, Mikami K, Ito Y, Wakai K, Tamakoshi A, JACC Study Group (2005) Risk factors for kidney cancer in a Japanese population: findings from the JACC Study. J Epidemiol 15 (Suppl 2): s203–11
Waters JS, Moss C, Pyle L, James M, Hackett S, A’hern R, Gore M, Eisen T (2004) Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Brit J Cancer 91: 1763–1768
Weaver DJ, Michalski K, Miles J (1989) Cytogenetics of bileratal renal cell carcinoma. J Urol 142: 497–700
Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N (2004) Conservative management of incidental contrast enhancing renal masses as safe alternative to invasive therapy. Urology 64 (1): 49–52
Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O’Malley CM, Lane BR, Gill IS, Novick AC (2008) Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 179: 1277–1283
Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, Overvad K, Becker N, Linseisen J, Trichopoulou A, Mountokalakis T, Trichopoulos D, Sieri S, Palli D, Vineis P, Panico S, Peeters PHM, Bueno-de-Mesquita HB, Verschuren WMM, Ljungberg B, Hallmans G, Berglund G, Gonzales CA, Dorronsoro M, Barricarte A, Tormo MJ, Allen N, Roddam A, Bingham S, Khaw KT, Rinaldi S, Ferrari P, Norat T, Riboli E (2008) Blood pressure and risk of renal cell carcinoma in the european prospective investigation into cancer and nutrition. Am J Epidemiol 167: 438–446
Weinblatt ME, Kahn E, Kochen J (1987) Renal cell carcinoma in patients with tuberous sclerosis. Pediatrics 80: 898
Weirich G, Glenn G, Junker K et al. (1998) Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 160: 335–340
West WH, Tauer KW, Yanelli IR, Marshall GD, Ott DW, Thurmann B, Oldham RK (1987) Constant-infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905
Wierecky J, Müller M, Brossat P (2006) Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55 (1): 63–67
Wiesner C, Jakse G, Rohde D (2002) Therapy of local recurrence of renal cell carcinoma. Oncol Rep 9: 189–92
Winter P, Miersch WD, Vogel J, Jaeger N (1990) On the nedessity of adrenal extirpation combined with radical nephrectomy. J Urol 144: 842–844
Wirth M (1991) Stellenwert der Interferone, des Interleukin 2 und des Tumornekrosefaktors in der Therapie des Nierenzellkarzinoms. Urologe A 30: 77–80
Wood L, Bukowski RM, Dreicer R, Elson P, Garcia JA, Gilligan T, Mekhail T, Rini BR (2008) Temsiroslismus (TEM) in metastatic renal cell carcinoma (mRCC): Safetey and efficacy in patients previously treated with VEGF-targeted therapy. ASCO A353
Woodward ER et al. (2000) Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 37: 348–353
Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER (2000) Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 37: 348–353
Woodward ER. Familial non-syndromic clear cell renal cell carcinoma. Curr Mol Med. 2004 Dec; 4 (8): 843–8.
Wotkowicz C, Libertino JA, Sorcini A, Mourtzinos A (2006) Management of renal cell carcinoma with vena cava and trial thrombus: minimal access vs median sternotomy with circulatory arrest. BJU Int 98: 289–297
Wullschleger S, Loewith R, Hall MN (2006) TOR signalling in growth and metabolism. Cell 124: 471–484
Yang JC, Haworth L, Sherry RM, Hwu P, Schwarzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (5): 427–434
Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR (2001) Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58 (2): 141–145
Yossepowitsch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo L (2008) Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 179: 2158–2163
Yuan J-M, Castealo JE, Gago-Dominguez M, Ross RK, Yu MC (1998) Hypertension, obesity and their medications in relatation to renal cell carcinoma. Br J Cancer. 77: 1508–1513
Zbar B, Tory K, Marino M et al. (1994) Hereditary papillary renal cell carcinomas. J Urol 151: 561
Zbar B, Glenn G, Lubensky IA et al. (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153: 907–12
Zincke H, Sen SE (1988) Experience with extracorporal surger and autotransplantation for renal cell and transitional cell cancer of the kidney. J Urol 140 (1): 25–27
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559–4566
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heidenreich, A., Doehn, C., Schenck, M., Jakse, G. (2014). Nierenzellkarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-35032-0_20
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35031-3
Online ISBN: 978-3-642-35032-0
eBook Packages: Medicine (German Language)